Cravens & Co Advisors’s GSK GSK Stock Holding History

Cravens & Co Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$388K	Sell	7,400 -351	-5%	-$18.6K	0.26%	54
2026 Q1	$428K	Buy	7,751 +184	+2%	+$9.97K	0.28%	48
2025 Q4	$378K	Sell	7,567 -189	-2%	-$8.81K	0.25%	48
2025 Q3	$335K	Sell	7,756 -3	-0%	-$117	0.23%	47
2025 Q2	$298K	Buy	7,759 +170	+2%	+$6.5K	0.22%	47
2025 Q1	$294K	Buy	+7,589	New	+$278K	0.23%	48
2024 Q4	–	Sell	-7,459	Closed	-$305K	–	65
2024 Q3	$305K	Sell	7,459 -881	-11%	-$36K	0.24%	51
2024 Q2	$321K	Sell	8,340 -197	-2%	-$8.29K	0.24%	57
2024 Q1	$366K	Sell	8,537 -382	-4%	-$15.8K	0.3%	54
2023 Q4	$331K	Sell	8,919 -315	-3%	-$11.3K	0.29%	58
2023 Q3	$335K	Sell	9,234 -99	-1%	-$3.51K	0.31%	58
2023 Q2	$333K	Sell	9,333 -76	-0.8%	-$2.73K	0.31%	56
2023 Q1	$335K	Buy	9,409 +3	+0%	+$105	0.31%	55
2022 Q4	$331K	Buy	+9,406	New	+$313K	0.31%	59

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Cravens & Co Advisors's GSK Position: Q2 2026 in Review

Cravens & Co Advisors reduced its GSK (GSK) stake by 4.5% in Q2 2026, selling an estimated $18.6K and leaving 7,400 shares worth $388K. The position accounts for 0.26% of the portfolio, ranked #54.

Cravens & Co Advisors first reported a position in GSK in Q4 2022 and has held it in 14 quarters since. The position peaked at $428K in Q1 2026. 1,042 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Cravens & Co Advisors held 7,400 shares of GSK worth $388K as of Q2 2026.
Cravens & Co Advisors sold 351 GSK shares in Q2 2026, an estimated $18.6K.
GSK made up 0.26% of Cravens & Co Advisors's portfolio in Q2 2026, its #54 holding.
Cravens & Co Advisors first reported a position in GSK in Q4 2022 and has held it in 14 quarters since.
Cravens & Co Advisors's GSK position peaked at $428K in Q1 2026.
1,042 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Cravens & Co Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.